Female MLH1 and MSH2 carriers had elevated SIRs for any cancer, colorectal, stomach, small bowel, urothelial, and endometrial cancer, which were all statistically significant, with the exception of stomach cancer in MLH1 carriers. Here, MLH1 is linked to endometrial cancer.